The iHealth’s COVID-19/Flu A&B 3-in-1 Antigen Rapid Test delivers results in 15 minutes. Credit: PRNewswire/ iHealth Labs, Inc.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for iHealth Labs’ new COVID-19/Flu A&B rapid test kit.

Intended to deliver results in 15 minutes, the 3-in-1 test kit is said to be one of the first over-the-counter rapid antigen tests for both Covid-19 and influenzas A and B in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is used for self-testing at home and is suitable for individuals aged two and above, with adult assistance required for children between the ages of two and 13 years.

Building on the user-friendly design of iHealth’s standalone at-home Covid test, the new test requires five drops on the test card, a slight increase from the previous three drops.

The lateral flow immunoassay displays results for Covid-19, influenza A, and influenza B.

The iHealth COVID-19/Flu A&B Rapid Test is designed for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

iHealth CEO Jack Feng said: “In the face of uncertainty surrounding symptoms such as fever, sneezing, cough, or fatigue and what illness they may be indicative of, our at-home 3-in-1 self-test offers peace of mind for parents who might be worried that their vulnerable young children have Covid-19 or the flu.

“As we did with the stand-alone at-home Covid test during the pandemic, our goal now with this second generation of at-home testing that introduces combination tests such as the 3-in-1, is to evolve with consumer and public healthcare needs to deliver products that address immediate concerns.”

Only those who have respiratory infection symptoms and indications consistent with Covid-19 within the first four days of symptom onset, are eligible for this test.

Last year, iHealth Labs said it manufactured more than 70 million Covid-19 at-home test kits at its facility in Irwindale, California.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact